Omeros shares fell 14% on October 16, 2026, following an unfavorable European regulatory opinion on narsoplimab, its treatment for a serious stem cell transplant complication. H.C. Wainwright maintained its Buy rating and $33 price target, saying the setback did not change its financial forecasts because its model already excluded European markets.
Key Takeaways
- CHMP upheld its negative opinion on narsoplimab after re-examining Omeros’ application.
- H.C. Wainwright had excluded European markets from its model in June, leaving its forecasts unchanged.
- The treatment remains approved and commercially available in the United States under the YARTEMLEA brand.
Table of Contents
- Omeros shares retreat after European re-examination
- Why the analyst’s forecasts did not change
- Omeros pursues access plans alongside U.S. sales
- Conclusion
Omeros shares retreat after European re-examination
Omeros’ October 16 regulatory announcement confirmed that the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a negative opinion following re-examination of the company’s application. The application sought authorization for narsoplimab to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy, known as TA-TMA.
The outcome leaves Omeros without the European authorization it sought. The company said there is no approved therapy for TA-TMA in Europe and that its plan to license European Union commercialization rights to a third party remains conditional on authorization.
The European setback is separate from the drug’s U.S. status. The Food and Drug Administration approved narsoplimab as YARTEMLEA in December 2025, and Omeros is selling it through its own U.S. field force.
| Item | Details |
|---|---|
| Original CHMP opinion | Negative opinion adopted in June 2026. |
| Re-examination outcome | Negative opinion announced October 16, 2026. |
| U.S. approved population | TA-TMA patients aged two years and older. |
| European commercial plan | Third-party licensing planned if EU authorization is granted. |
Why the analyst’s forecasts did not change
H.C. Wainwright reaffirmed its Buy recommendation and $33 target on October 16. The firm had removed European markets from its model in June, so the latest regulatory outcome did not require it to reduce the forecasts underpinning that target.
That distinction explains how an adverse regulatory development can coexist with an unchanged analyst recommendation: the model already assumed no European contribution. The rating and target remain the investment firm’s assessment, not company guidance or a guaranteed future share price.
Omeros pursues access plans alongside U.S. sales
Omeros said it is working to enable fully reimbursed, named-patient access to YARTEMLEA where permitted in Europe and other regions. This is an access initiative, not an announcement of European marketing approval.
Citing increasing demand for U.S. commercial supply, the company also informed CHMP that it intends to terminate its compassionate-use program. Patients already receiving treatment through that program will receive enough drug to complete their treatment courses.
The company is also pursuing additional uses for its MASP-2 drug franchise. It plans to begin studies in acute respiratory distress syndrome and prevention of high-risk TA-TMA in pediatric patients later in 2026; those studies had not been announced as started.
Conclusion
The European setback leaves H.C. Wainwright’s already Europe-excluded forecasts unchanged, but it does not resolve Omeros’ authorization hurdle. The next stated development milestones are the additional clinical studies planned to begin later in 2026, alongside the company’s ongoing U.S. commercialization and overseas access efforts.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
